EODData

MEMBERSHIP REGISTER LOG IN

FRA, HPHA: Heidelberg Pharma AG

06 Nov 2025
LAST:

3.060

CHANGE:
 0.02		OPEN:
3.130		HIGH:
3.210		ASK:
0.000		VOLUME:
1.5K
CHG(%):
0.66		PREV:
3.040		LOW:
3.060		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
06 Nov 253.1303.2103.0603.0601.5K
05 Nov 252.9503.0402.9503.040500
04 Nov 252.9302.9302.9302.930320
31 Oct 252.9302.9302.9202.920320
30 Oct 252.9402.9402.9302.930320
29 Oct 252.9102.9202.9102.920320
28 Oct 253.0203.0202.9202.920320
27 Oct 253.0403.0403.0103.010320
24 Oct 253.1803.1803.0203.0201.8K
23 Oct 253.2103.2803.0803.0805.8K

COMPANY PROFILE

Name:Heidelberg Pharma AG
About:Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, the United States, and internationally. Its lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company develops HDP-102, an antibody and the compound Amanitin, which has completed preclinical development for the treatment of non-Hodgkin lymphoma; HDP-103, a proprietary ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors; HDP-201 for the treatment of colorectal cancer; and TAK-ATAC for the treatment of oncology. It also develops TLX250-CDx, a diagnostic antibody for kidney cancer that is in Phase III trials, as well as for the treatment of bladder cancer. In addition, the company develops TLX250 (girentuximab), a therapeutic antibody, which is in Phase II study for the treatment of kidney cancer; and RHB-107, an orally serine protease inhibitor that is in Phase II study to treat COVID-19. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is headquartered in Ladenburg, Germany.
Sector:Healthcare
Industry:Biotechnology
Address:Gregor-Mendel-Strasse 22, Ladenburg, Germany, 68526
Website:https://heidelberg-pharma.com
ISIN:DE000A11QVV0
LEI:391200E09XYBYITR1W32

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-6.98 
Forward P/E:-3.91 
PEG Ratio:-0.13 
Price to Sales:45.90 
Price to Book:13.14 
Profit Margin:0.74 
Operating Margin:-214.48 
Return on Assets:-0.32 
Return on Equity:-1.13 
Revenue:3.04M 
Shares:46.61M 
Market Cap:142.61M 

TECHNICAL INDICATORS

MA5:2.982.8%
MA10:2.982.6%
MA20:2.963.4%
MA50:3.225.1%
MA100:3.7522.7%
MA200:3.318.3%
STO9:48.28
STO14:51.11
RSI14:57.14
WPR14:-8.00 
MTM14:0.13
ROC14:0.04 
ATR:0.10 
Week High:3.214.9%
Week Low:2.924.8%
Month High:3.287.2%
Month Low:2.838.3%
Year High:5.3675.2%
Year Low:2.1045.4%
Volatility:6.65 

RECENT SPLITS

Date Ratio
18 Jul 20141-4